ABCB4 mutation ID’d as cause of woman’s recurrent cholestasis
A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing, to have a mutation in…
News
Icosabutate fails MASH Phase 2 trial but shows some benefits in liver
Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
More collaborative Alagille research is needed, review study says
More collaborative research is needed to better understand Alagille syndrome and to help overcome challenges related to diagnosing and treating it, according to a…
Bemnifosbuvir-ruzasvir Phase 3 trials in hepatitis C launch in April
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Canadian scientists given grant to advance ways of treating PSC
Conscience, a Canadian nonprofit, has awarded CA$461,241 (nearly $320,000) to a research project aiming to provide preclinical data that could lead to new approaches…
ICP incidence at nearly 3% worldwide, but varies by region
Intrahepatic cholestasis of pregnancy (ICP) is estimated to affect nearly 3% of pregnant women worldwide, with the highest incidence reported in Asia and the…
Efruxifermin reverses MASH-related cirrhosis in Phase 2 trial
Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a still-functioning liver, among adults with metabolic dysfunction-associated…
Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
Domenic Frappolli, who was born with biliary atresia, was named the American Liver Foundation’s (ALF) 2025 National LIVEr Champion. The foundation is spotlighting…
Researchers uncover how hepatitis B virus can persist in liver cells
Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…
CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
Chemomab Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the best path toward regulatory approval of its investigational therapy nebokitug,…
